Head and Neck CancerNCT07852949
Understanding the Role of MyCareGorithm as a Visual Digital Platforms in Cancer Treatment Education and Patient Comprehension of Oncology Treatment Plans
A study testing Survey in people with Head and Neck Cancer and Prostate Cancer, run by M.D. Anderson Cancer Center at 1 site in United States.
Trial summary
The purpose of this research study is to learn if a digital communication tool can improve how well patients with head and neck cancer and their caregivers understand the disease and treatment plan after their first consultation visit with the doctor/nurse practitioner. Read more about this study
- Who is it for?
- Ages 18 to 100 yearsHealthy volunteers can take part
- Conditions the study is for
- Head and Neck Cancer, Prostate Cancer
- What is being tested?
- Survey
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 94 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Mar 2027to 1 Dec 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 100 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Patients
- Adults aged 18 to 100 years.
- Diagnosed with head and neck cancer (all histologies included).
- Receiving treatment for head and neck and prostate cancer at MDACC
- Able to speak and understand English
- Caregivers
Show all 12Show fewer
- Adults (≥18 years old).
- Identified as a caregiver to a patient who meets the above patient inclusion criteria.
- Able to speak and understand English.
- Providers
- Doctors or nurse practitioners practicing in the field of radiation oncology and actively participating in initial consultations for patients with head and neck cancer and prostate cancer.
- Must complete the provider survey after the consultation.
Who cannot join
- Patients
- Individuals without a diagnosis of head and neck cancer or prostate cancer.
- Patients who do not speak English (since the digital tool is not translated).
- Caregivers
- Adults who are not caregivers of the eligible patient
- Caregivers who do not speak English (tool not translated).
- Providers
- Doctors or nurse practitioners not practicing in the field of radiation oncology and not part of the initial consultation process.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
UT MD Anderson
Houston, Texas, 77030
Steven J Frank, MD, 713-563-3601, sjfrank@mdanderson.org
Steven Frank, MD
About this study
The purpose of this research study is to learn if a digital communication tool can improve how well patients with head and neck cancer and their caregivers understand the disease and treatment plan after their first consultation visit with the doctor/nurse practitioner.
Read the detailed description
Primary Objective:
The primary objective of this pilot study is to determine whether use of a novel digital visual communication tool improves patient understanding and satisfaction with their initial multidisciplinary consultation for head and neck and prostate cancer. Specifically, the study seeks to answer the scientific question:
- Do at least 75% of newly diagnosed head and neck and prostate cancer patients report being "satisfied" (≥4 positive responses on a 6-item survey) after use of the digital communication tool, and is this proportion significantly greater than 50%?
Secondary Objectives:
Caregiver Understanding and Satisfaction
- What proportion of caregivers of newly diagnosed patients report satisfaction with their understanding of the patient's disease and treatment after using the tool, and how confident can we be in this estimate (95% Clopper-Pearson CI)?
Provider Experience and Communication Effectiveness
- What proportion of providers report satisfaction (≥5 positive responses on a 7-item survey) with the tool's ability to improve communication efficiency and consultation quality for patients they treated?
- Conditions
- Head and Neck Cancer, Prostate Cancer
- Being tested
- Survey
- Medical subject headings
- Head and Neck Neoplasms, Prostatic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SurveyOther
A 6-item structured questionnaire with Yes/No response options, followed by one open-ended free-text question.
| Study group | Role | What they receive |
|---|---|---|
| Patient/Caregiver: Use of MyCareGorithm | Experimental | Following use of the digital visual communication tool by the provider, patients and any accompanying caregivers will be asked to complete their surveys via REDCap. Providers will complete their survey immediately after the consultation with each participating patient, also via REDCap. Each survey requires approximately 5 minutes to complete. No follow-up surveys or repeat administrations are planned. Receives: Other: Survey |
What is being measured
The primary outcome is the main question the study is designed to answer.
Safety and Adverse Events (AEs)
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Measured: Through study completion; an average of 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Oct 2026
- Study start1 Mar 2027 (estimated)
- Primary completion1 Dec 2027 (estimated)
- Study completion1 Dec 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Head and Neck CancerStudies of the same condition, open and under way.
- More trials run by M.D. Anderson Cancer CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Device feasibility
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 94 participants (estimated)
Sponsor and investigators
- Lead sponsor
- M.D. Anderson Cancer Center
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Steven J Frank, MD, Principal investigator, UT MD Anderson
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07852949
- Sponsor's protocol ID
- 2026-1108
- Other IDs
- NCI-2026-07264
- Status last verified
- Sep 2026
- First submitted
- 28 Sep 2026
- Last updated
- 1 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 1 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Understanding the Role of MyCareGorithm as a Visual Digital Platforms in Cancer Treatment Education and Patient Comprehension of Oncology Treatment Plans
- ClinicalTrials.gov ID
- NCT07852949
- Acronym / sponsor ID
- 2026-1108
- Conditions
- Head and Neck Cancer, Prostate Cancer
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 94 participants (estimated)
- Lead sponsor
- M.D. Anderson Cancer CenterUniversity, hospital or other
- Study start
- 1 Mar 2027 (estimated)
- Primary completion
- 1 Dec 2027 (estimated)
- Study completion
- 1 Dec 2029 (estimated)
- First posted
- 1 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this research study is to learn if a digital communication tool can improve how well patients with head and neck cancer and their caregivers understand the disease and treatment plan after their first consultation visit with the doctor/nurse practitioner.
Detailed description
Primary Objective:
The primary objective of this pilot study is to determine whether use of a novel digital visual communication tool improves patient understanding and satisfaction with their initial multidisciplinary consultation for head and neck and prostate cancer. Specifically, the study seeks to answer the scientific question:
- Do at least 75% of newly diagnosed head and neck and prostate cancer patients report being "satisfied" (≥4 positive responses on a 6-item survey) after use of the digital communication tool, and is this proportion significantly greater than 50%?
Secondary Objectives:
Caregiver Understanding and Satisfaction
- What proportion of caregivers of newly diagnosed patients report satisfaction with their understanding of the patient's disease and treatment after using the tool, and how confident can we be in this estimate (95% Clopper-Pearson CI)?
Provider Experience and Communication Effectiveness
- What proportion of providers report satisfaction (≥5 positive responses on a 7-item survey) with the tool's ability to improve communication efficiency and consultation quality for patients they treated?
Study design
- Primary purpose
- Device feasibility
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patient/Caregiver: Use of MyCareGorithm | Experimental | Other: SurveyFollowing use of the digital visual communication tool by the provider, patients and any accompanying caregivers will be asked to complete their surveys via REDCap. Providers will complete their survey immediately after the consultation with each participating patient, also via REDCap. Each survey requires approximately 5 minutes to complete. No follow-up surveys or repeat administrations are planned. |
Who may qualify
- Ages
- 18 to 100 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (12 listed)
- Patients
- Adults aged 18 to 100 years.
- Diagnosed with head and neck cancer (all histologies included).
- Receiving treatment for head and neck and prostate cancer at MDACC
- Able to speak and understand English
Key exclusion criteria (8 listed)
- Patients
- Individuals without a diagnosis of head and neck cancer or prostate cancer.
- Patients who do not speak English (since the digital tool is not translated).
- Caregivers
- Adults who are not caregivers of the eligible patient
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SurveyA 6-item structured questionnaire with Yes/No response options, followed by one open-ended free-text question. | Other | Patient/Caregiver: Use of MyCareGorithm |
Primary outcome
Safety and Adverse Events (AEs)
Time frame: Through study completion; an average of 1 year
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Oct 2026.
- UT MD Anderson WebsiteLink provided by the sponsor.
Related trials for Head and Neck Cancer
RecruitingPhase 2
Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC
Esophageal Squamous Cell Carcinoma, Immunotherapy
RecruitingPhase 1/2
Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
RecruitingPhase 2
Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer
Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
RecruitingPhase 1
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Breast Neoplasms, Colorectal Neoplasms
Active, not recruitingPhase 3
Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer
Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Steven J Frank, MD principal investigator
UT MD Anderson
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Survey in people with Head and Neck Cancer and Prostate Cancer, run by M.D. Anderson Cancer Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 12 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 1 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Steven J Frank, MD ((713) 563-3601, sjfrank@mdanderson.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Safety and Adverse Events (AEs) (time frame: Through study completion; an average of 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Oct 2026.